In order to allow more elderly to benefit from our Community Antibody Test Pilot Scheme, we once again collaborated with the Neighbourhood Advice-Action Council (NAAC) and Abbott to conduct blood antibody tests for the elderly in the nursing home to identify whether their bodies produced antibodies against COVID-19* after being infected or vaccinated.
Due to the overwhelming response to this scheme, we will continue to visit different community centres to conduct testing for those in need, please pay close attention to our latest news!
* The Panbio™ COVID-19 IgG Rapid Test Device detects immunoglobulin (IgG) antibodies to the SARS-CoV-2 spike protein receptor binding domain (S1-RBD). This test can identify individuals with prior COVID-19 infection or post vaccination antibodies. This antibody test can help you determine if an individual has developed antibodies post infection and/or post vaccination. Conduct serological surveillance. This is done by taking “snapshots” of the percentage of people who have antibodies against SARS-CoV-2 (also called the seroprevalence) at different time points. This can provide information about antibody trends and help professionals determine the burden of severe disease on the healthcare system. Learn more: https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-igg-test.html?c=WW
Comments